Approval · Notice of Compliance 29634 · 2022
PAXLOVID: Notice of Compliance 29634
Issued June 13, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29634
- Date
- June 13, 2022
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- A new dose pack specifically for patients with moderate renal impairment who require nirmatrelvir dose reduction.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PAXLOVID | 02527804 | Cancelled Post Market |
Medicinal ingredients
- RITONAVIR 100 MG per TAB
- NIRMATRELVIR 150 MG per TAB